Found 5 Polyneuropathy trials
A listing of Polyneuropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Phase 3
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. For those with : a. Stage 1 or Stage 2 according to the Familial Amyloid Polyneuropathy (FAP) or Coutinho Stage b. Documented genetic mutation in the TTR gene …
TEGSEDI Administration in Patients with Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)
Phase 4
TEGSEDI (also known as inotersen) is a medicine that has been approved in the United States, Europe and Canada to treat polyneuropathy (nerve damage) caused by hereditary transthyretin amyloidosis (hATTR-PN) in adults. hATTR-PN is a rare genetic disease that worsens over time if left untreated. This research study will examine …
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy ( (ADHERE)
Phase 2
Study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
Argenx 113-1902 Study
The main goal of this study is to look at the long-term safety and effect of a drug called efgartigimod PH20 SC in people with chronic inflammatory demyelinating polyneuropathy (CIDP).The active substance that is being tested is called efgartigimod (ARGX-113), which is co formulated with PH20 for Subcutaneous injection (called …
TEGSEDI study
Phase 4
This research study is being done at the request of the US Food & Drug Administration (FDA) to collect additional safety information for the commercially available drug TEGSEDI. This research study is being conducted to examine any changes in health or side effects occurring within 24 hours following treatment with …
